Oricula Therapeutics Announces FDA Approval for ORC-13661 Human Trials

In animal studies, ORC-13661 reportedly provided “highly significant” protection of hearing in rats exposed to high doses of aminoglycoside antibiotics, a common cause of human hearing loss, according to the company.